Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2026 · third_quarter · Q3
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Source: Senate LDA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2026
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2026
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2026 · second_quarter · Q2
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE